title: The prognostic value of a histologic grading system, DNA profile, and MIB-1 expression in early stages of cervical squamous cell carcinomas.
abstract: This study evaluated the prognostic importance of a new grading system focusing on the invasive tumor front, DNA profile, and the proliferation marker MIB-1. A complete geographic series of 172 women treated with radical hysterectomy (Wertheim-Meigs) for FIGO stage I-II cervical carcinomas was the target population. The analyses were performed on 141 (82%) squamous cell carcinomas of the complete series. During the period of observation (mean 222 months), 17 recurrences (12.1%) were encountered. Prognostic factors for disease-free survival were lymph node status (P < 0.000001), radical surgical margins (P = 0.00004), and tumor size (P = 0.002). The complete score of the invasive front grading system (IFG), and the individual scores of two variables-pattern of invasion and host response-were all significantly (P = 0.002, P = 0.007, P = 0.0001) associated with pelvic lymph node metastases. Host response was the single most important factor in the IFG system, and it was superior to the complete score in predicting lymph node metastases. The total IFG score was also a significant (P = 0.003) prognostic factor for disease-free survival. DNA ploidy, S-phase fraction, and MIB-1 expression were nonsignificant factors in predicting pelvic lymph node metastases and disease-free survival of the patient. The IFG in the original or modified versions could predict low- and high-risk groups of tumors and therefore be of value in treatment planning for these patients.
authors.affiliation: Department of Gynecological Oncology, Orebro University Hospital, SE-701 85 Orebro, Sweden. marianne.graflund@orebroll.se
authors.forename: Marianne
authors.initials: M
authors.lastname: Graflund
authors.forename: B
authors.initials: B
authors.lastname: Sorbe
authors.forename: M
authors.initials: M
authors.lastname: Bryne
authors.forename: M
authors.initials: M
authors.lastname: Karlsson
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000473:pathology / Q000556:secondary / Q000628:therapy; D034961:Antigens, Nuclear; D018196:Carcinoma, Adenosquamous / Q000737:chemistry / Q000473:pathology / Q000556:secondary / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000473:pathology* / Q000556:secondary / Q000628:therapy; D004273:DNA, Neoplasm / Q000032:analysis*; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007044:Hysterectomy; D007150:Immunohistochemistry; D019394:Ki-67 Antigen; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000032:analysis*; D010386:Pelvic Neoplasms / Q000556:secondary; D011003:Ploidies; D011237:Predictive Value of Tests; D011379:Prognosis; D016196:S Phase; D002583:Uterine Cervical Neoplasms / Q000737:chemistry / Q000473:pathology* / Q000628:therapy
chemical_list: D034961:Antigens, Nuclear; D004273:DNA, Neoplasm; D019394:Ki-67 Antigen; D009687:Nuclear Proteins